METTL16

Across TCGA pan-cancer cohorts, METTL16 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated METTL16 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher METTL16 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated METTL16 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and UCEC are the cancer types where METTL16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.761	0.468	.021	18	view →
CCRCC	OS	Median	All	1.000	0.675	.015	10	view →
UCEC	DFS	Quartile	All	0.839	0.980	.020	4	view →
HNSC	DFS	Tertile	IV	0.515	0.868	.010	4	view →
LSCC	DFS	Tertile	All	1.000	0.927	.016	4	view →
PDAC	DFS	Quartile	III,IV	0.969	0.607	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

METTL16–LUAD (OS)

Open the LUAD breakdown →